NewsEpisurf Medical continues its communication with the US Food and Drug Administration (FDA) regarding appropriate route for market acceptance in the US

In July 2016, Episurf Medical participated in a pre-submission meeting with the FDA in Washington. Following this meeting, Episurf Medical submitted a 513(g) Request for Information for obtaining FDA’s views about the classification and the regulatory requirements that may be applicable to the Episealer device.

Episurf Medical has now received feedback from the FDA regarding the 513(g) request. The feedback is not decisive and opens up various alternatives for Episurf Medical to assess; further interaction with the FDA has been initiated. There are several factors to consider when deciding what regulatory pathway to select and what kind of application to submit to the FDA. Episurf Medical has started an internal process to decide on a regulatory pathway for application for US market acceptance. The Company expects to complete its review and reach a decision by the third quarter of 2017.

“With our European launch of the Episealer technology now well underway, we are eager to move on with the strategic development and regulatory process for the important North American market. We are happy to now have feedback on our 513(g) application, and we look forward to continuing our constructive integration with FDA in determining our best route forward.” comments Pål Ryfors, Acting CEO and CFO, Episurf Medical.

For more information, please contact:
Pål Ryfors, acting CEO, Episurf Medical
Tel: +46 (0) 709 62 36 69
Email: pal.ryfors@episurf.com